Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
Alexander EgebergJason E HawkesNajwa SomaniRussel BurgeKyoungah SeeGaia GalloMissy McKean-MatthewsMelinda GooderhamGeorge HanApril ArmstrongPublished in: Dermatology and therapy (2024)
NCT01474512 (UNCOVER-1), NCT01597245 (UNCOVER-2), and NCT01646177 (UNCOVER-3).